TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

17 Apr 2025 13:54:18 By Nasdaq GlobeNewswire

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

15 Apr 2025 13:03:00 By Nasdaq GlobeNewswire

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

14 Apr 2025 12:53:50 By Nasdaq GlobeNewswire

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States

09 Apr 2025 13:45:39 By Nasdaq GlobeNewswire

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs

08 Apr 2025 16:53:05 By Nasdaq GlobeNewswire

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission

07 Apr 2025 14:58:27 By Nasdaq GlobeNewswire

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

26 Mar 2025 14:12:23 By Nasdaq GlobeNewswire

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

25 Mar 2025 12:11:06 By Nasdaq GlobeNewswire

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

10 Mar 2025 11:40:32 By Nasdaq GlobeNewswire

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

07 Mar 2025 15:09:46 By Nasdaq GlobeNewswire

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

03 Mar 2025 11:52:45 By Nasdaq GlobeNewswire

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

28 Feb 2025 12:17:46 By Nasdaq GlobeNewswire

Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

21 Feb 2025 14:28:56 By Nasdaq GlobeNewswire

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

14 Feb 2025 17:31:40 By Nasdaq GlobeNewswire

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

14 Feb 2025 12:16:54 By Nasdaq GlobeNewswire

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

14 Feb 2025 10:52:04 By Nasdaq GlobeNewswire

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

13 Feb 2025 15:34:10 By Nasdaq GlobeNewswire

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

10 Feb 2025 16:30:20 By Nasdaq GlobeNewswire

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure

07 Feb 2025 13:56:54 By Nasdaq GlobeNewswire

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

28 Jan 2025 14:49:48 By Nasdaq GlobeNewswire